Last reviewed · How we verify
Ademetionine 3
Ademetionine 3 is a Methyl donor / Hepatoprotective agent Small molecule drug developed by Zhejiang Hisun Pharmaceutical Co. Ltd.. It is currently FDA-approved for Liver disease and hepatic dysfunction, Cholestasis, Hepatic cirrhosis.
Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.
Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function. Used for Liver disease and hepatic dysfunction, Cholestasis, Hepatic cirrhosis.
At a glance
| Generic name | Ademetionine 3 |
|---|---|
| Sponsor | Zhejiang Hisun Pharmaceutical Co. Ltd. |
| Drug class | Methyl donor / Hepatoprotective agent |
| Target | S-adenosylmethionine (SAM) / Methyltransferase cofactor |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Ademetionine (also known as S-adenosyl methionine or SAM) is an endogenous compound that serves as the primary methyl donor in the body. It participates in critical methylation reactions involved in neurotransmitter synthesis, phospholipid metabolism, and antioxidant defense. By restoring depleted SAM levels, it supports hepatocyte regeneration and improves liver function in conditions characterized by SAM deficiency.
Approved indications
- Liver disease and hepatic dysfunction
- Cholestasis
- Hepatic cirrhosis
Common side effects
- Gastrointestinal disturbance
- Nausea
- Diarrhea
Key clinical trials
- Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia (NA)
- Trial of Rice-Based F-75 in Severe Malnutrition & Persistent Diarrhea in Children (SAM-RICE Study) (NA)
- Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly (NA)
- Muscadine Plus (MPX) In Men With Prostate Cancer (PHASE3)
- Patient-centered Mobile Technology Interventions to Improve Maternal Health in Uganda (NA)
- Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 (PHASE1, PHASE2)
- Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation (NA)
- Researching Alveolar Macrophage Improvements With Supplements in HIV (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ademetionine 3 CI brief — competitive landscape report
- Ademetionine 3 updates RSS · CI watch RSS
- Zhejiang Hisun Pharmaceutical Co. Ltd. portfolio CI
Frequently asked questions about Ademetionine 3
What is Ademetionine 3?
How does Ademetionine 3 work?
What is Ademetionine 3 used for?
Who makes Ademetionine 3?
What drug class is Ademetionine 3 in?
What development phase is Ademetionine 3 in?
What are the side effects of Ademetionine 3?
What does Ademetionine 3 target?
Related
- Drug class: All Methyl donor / Hepatoprotective agent drugs
- Target: All drugs targeting S-adenosylmethionine (SAM) / Methyltransferase cofactor
- Manufacturer: Zhejiang Hisun Pharmaceutical Co. Ltd. — full pipeline
- Therapeutic area: All drugs in Hepatology / Gastroenterology
- Indication: Drugs for Liver disease and hepatic dysfunction
- Indication: Drugs for Cholestasis
- Indication: Drugs for Hepatic cirrhosis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing